Maurissen Thomas L, Pavlou Georgios, Bichsel Colette, Villaseñor Roberto, Kamm Roger D, Ragelle Héloïse
Roche Pharma Research and Early Development, Immunology, Infectious Diseases and Ophthalmology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland.
Department of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Ave., MIT Building, Room NE47-321, Cambridge, MA 02139, USA.
J Pers Med. 2022 Jan 24;12(2):148. doi: 10.3390/jpm12020148.
Blood-neural barriers regulate nutrient supply to neuronal tissues and prevent neurotoxicity. In particular, the inner blood-retinal barrier (iBRB) and blood-brain barrier (BBB) share common origins in development, and similar morphology and function in adult tissue, while barrier breakdown and leakage of neurotoxic molecules can be accompanied by neurodegeneration. Therefore, pre-clinical research requires human in vitro models that elucidate pathophysiological mechanisms and support drug discovery, to add to animal in vivo modeling that poorly predict patient responses. Advanced cellular models such as microphysiological systems (MPS) recapitulate tissue organization and function in many organ-specific contexts, providing physiological relevance, potential for customization to different population groups, and scalability for drug screening purposes. While human-based MPS have been developed for tissues such as lung, gut, brain and tumors, few comprehensive models exist for ocular tissues and iBRB modeling. Recent BBB in vitro models using human cells of the neurovascular unit (NVU) showed physiological morphology and permeability values, and reproduced brain neurological disorder phenotypes that could be applicable to modeling the iBRB. Here, we describe similarities between iBRB and BBB properties, compare existing neurovascular barrier models, propose leverage of MPS-based strategies to develop new iBRB models, and explore potentials to personalize cellular inputs and improve pre-clinical testing.
血-神经屏障调节神经元组织的营养供应并预防神经毒性。特别是,血-视网膜内屏障(iBRB)和血脑屏障(BBB)在发育过程中有共同的起源,在成年组织中具有相似的形态和功能,而屏障破坏和神经毒性分子的泄漏可能伴随着神经退行性变。因此,临床前研究需要能够阐明病理生理机制并支持药物研发的人体体外模型,以补充预测患者反应不佳的动物体内模型。先进的细胞模型,如微生理系统(MPS),在许多器官特异性情况下再现组织的结构和功能,具有生理相关性、针对不同人群进行定制的潜力以及用于药物筛选的可扩展性。虽然已经为肺、肠道、脑和肿瘤等组织开发了基于人体的MPS,但针对眼组织和iBRB建模的综合模型却很少。最近使用神经血管单元(NVU)的人类细胞建立的BBB体外模型显示出了生理形态和通透性值,并再现了可能适用于iBRB建模的脑神经系统疾病表型。在此,我们描述了iBRB和BBB特性之间的相似性,比较了现有的神经血管屏障模型,提出利用基于MPS的策略开发新的iBRB模型,并探索个性化细胞输入和改进临床前测试的潜力。